Dataset from A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults With Major Depressive Disorder
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/00007068
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the efficacy of vortioxetine (5, 10, and 20 mg)
versus placebo during the first 28 weeks of the 32-week double-blind treatment period in the
prevention of relapse in participants with MDD who responded to acute treatment with
vortioxetine 10 mg.
创建时间：
2025-11-24
